
Actithera appoints new CMO to advance radiopharmaceuticals
Radiopharmaceutical biotech company Actithera has appointed Darshan Dalal as Chief Medical Officer. Dalal will lead the clinical strategy and build the clinical development organisation as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic. The company is also building its pipeline of differentiated precision-engineered radiopharmaceuticals. Dalal… Read More

